The basal level of inflammation during cardiogenic shock is a strong independent risk marker of mortality.

9 March 2024 (16:20 - 16:32)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Francois Roubille

University Hospital Arnaud de Villeneuve, Montpellier (France)

4 More presentations in this session

Presentation thumbnail

Dual antiplatelet therapy versus oral anticoagulation plus antiplatelet monotherapy in patients with acute coronary syndrome and coronary artery ectasia: OVER-TIME randomized clinical trial

Doctor D. Araiza Garaygordobil (Ciudad de Mexico, MX)

Presentation thumbnail

Prehospital risk assessment and direct transfer to a percutaneous coronary intervention centre in suspected acute coronary syndrome: 1 year follow-up of the TRIAGE-ACS study

Mr J. Demandt (Eindhoven, NL)

Presentation thumbnail

Early left ventricular unloading or conventional approach after venoarterial extracorporeal membrane oxygenation: One-year outcomes of the EARLY-UNLOAD randomized clinical trial

Assistant Professor Y. Lim (Gwangju, KR)

Presentation thumbnail

Targeted mild hypercapnia is associated with reduced hs-Troponin T release after acute myocardial infarction and out-of-hospital cardiac arrest. A sub-study of the TAME trial.

Doctor M. Baumann Melberg (Oslo, NO)

Access the full session

Session thumbnail

Late-breaking science

The Event

Event poster

ESC Acute CardioVascular Care 2024

9 March 2024 16:20 CET

You may be interested in

Congress Presentation

Does inflammation matter in cardiogenic shock?

Congress Presentation

Targeting inflammation: a new frontier in managing cardiogenic shock?

Congress Presentation

Association of inflammation with shock severity, 30-day mortality and therapy response in patients with cardiogenic shock

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources